Bladder cancer.

  title={Bladder cancer.},
  author={H. Ozen},
  journal={Current opinion in oncology},
  volume={10 3},
  • H. Ozen
  • Published 1998
  • Medicine
  • Current opinion in oncology
Identification of genetic alterations in bladder cancer is proceeding very rapidly. The most common genetic alteration identified to date in bladder cancer is loss of heterozygosity of chromosome 9, suggesting a possible tumor-suppressor gene on this chromosome. Because none of the Ta tumors showed loss of heterozygosity of 9p, it may be possible to speculate that inactivation of a gene located on 9q may be the earlier event. The genes p53 and pRb have been associated with disease progression… Expand
Bladder Cancer
Loss of heterozygosity of chromosome 9p and 9q has been shown to be a crucial event in the transition of normal urothelium to papillary transitional cell carcinoma while p53 is primarily involved in the development of carcinoma in situ. Expand
A population-based study of immunohistochemical detection of p53 alteration in bladder cancer
The data indicate that population-based approaches to somatic alteration of p53 in bladder cancer are crucial to understanding the relationship of p 53 changes to aetiology and the outcome of this disease, and suggest that the pattern of immunohistochemical staining may represent distinct, discernible phenotypes. Expand
Bladder Cancer: A Simple Model Becomes Complex
Recent progress in the genome-wide analysis of bladder cancer is summarized, non-genetic, genetic and epigenetic factors causing extensive gene mis-regulation in malignant cells are analysed, and it is revealed that bladder cancers is far to be considered a simple model of malignancy. Expand
Molecular Basis of Urinary Bladder Cancer
It is hoped that a thorough understanding of the molecular basis of urothelial cancer will facilitate early diagnosis and will lead to development of new modalities for the management and treatment of these carcinomas. Expand
TP53 alterations and patterns of carcinogen exposure in a U.S. population‐based study of bladder cancer
There is exposure‐specific heterogeneity in inactivation of the TP53 pathway in bladder cancers and that integration of the spectrum of pathway alterations in population‐based approaches (capturing the full range of exposures to bladder carcinogens) may provide important insights into bladder tumorigenesis. Expand
Loss of Tumor Suppressor Gene Function in Human Cancer: An Overview
A revised multiple-hit model is proposed that will enable the identification of novel TSGs that can be used as prognostic and predictive biomarkers of cancer. Expand
Epigenetic Alterations in Bladder Cancer and Their Potential Clinical Implications
The epigenetic abnormalities associated with UC would make it an excellent target for epigenetic therapy, which is currently approved for the treatment of a few hematological malignancies, but future research is needed to address efficacy and potential toxicity issues. Expand
Detection of Bladder Cancer in Urine by a Tumor Suppressor Gene Hypermethylation Panel
Promoter hypermethylation of tumor suppressor genes is common in bladder cancer and was found in all grades and stages of tumors examined, and may enhance early detection of bladder cancer using a noninvasive urine test. Expand
PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non‐muscle invasive tumors
Interestingly, the presence of PIK3CA gene alterations, and in particular gene mutations, is significantly associated with reduced recurrence of NMIBC patients, and these findings may have high relevance in terms of using PI3K‐targeted therapies for BC treatment. Expand
Disruption of the FA/BRCA pathway in bladder cancer
Bladder carcinomas frequently show extensive deletions of chromosomes 9p and/or 9q, potentially including the loci of the Fanconi anemia genes FANCC and FANCG, and the possibility of disruption of the FA/BRCA DNA repair pathway in bladder tumors is suggested. Expand